Literature DB >> 11745016

Anticomplement activity of terpenoids from the spores of Ganoderma lucidum.

B S Min1, J J Gao, M Hattori, H K Lee, Y H Kim.   

Abstract

A new lanostane-type terpenoid, lucidenic acid SP1 (1), was isolated from a CHCl(3)-soluble fraction of Ganoderma lucidum spores together with four other known compounds (2 - 5). The structure of lucidenic acid SP1 was determined to be 3 beta,7 beta-dihydroxy-4,4,14 alpha-trimethyl-11,15-dioxo-5 alpha-chol-8-en-24-oic acid by spectroscopic means including 2D-NMR. Twelve triterpenes (1-12) isolated from G. lucidum spores were investigated in vitro for their anticomplementary activity. Compounds 1 - 5 were inactive, whereas ganoderiol F (8), ganodermanondiol (9) and ganodermanontriol (10) showed a strong anticomplement activity against the classical pathway (CP) of the complement system with IC(50) values of 4.8, 41.7, and 17.2 microM, respectively. The potency of these triterpene alcohols (8-10) in inhibiting CP activity was improved when the number of hydroxymethyl groups on the side chain moiety is increased. On the other hand, the ganoderic acids 1-7, which contain a carboxyl group in the side chain, and lucidumols A and B (11, 12) had little activity on this system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745016     DOI: 10.1055/s-2001-18854

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  9 in total

1.  Analysis of triterpenoids in ganoderma lucidum using liquid chromatography coupled with electrospray ionization mass spectrometry.

Authors:  Min Yang; Xiaoming Wang; Shuhong Guan; Jiameng Xia; Jianghao Sun; Hui Guo; De-An Guo
Journal:  J Am Soc Mass Spectrom       Date:  2007-03-26       Impact factor: 3.109

2.  Triterpenoids from the spores of Ganoderma lucidum.

Authors:  Bingji Ma; Wei Ren; Yan Zhou; Jinchuan Ma; Yuan Ruan; Chun-Nan Wen
Journal:  N Am J Med Sci       Date:  2011-11

3.  Identification and characterization of a novel diterpene gene cluster in Aspergillus nidulans.

Authors:  Kirsi Bromann; Mervi Toivari; Kaarina Viljanen; Anu Vuoristo; Laura Ruohonen; Tiina Nakari-Setälä
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

Review 4.  Antiinflammatory and immunomodulating properties of fungal metabolites.

Authors:  Cristina Lull; Harry J Wichers; Huub F J Savelkoul
Journal:  Mediators Inflamm       Date:  2005-06-09       Impact factor: 4.711

5.  The pharmacological potential of mushrooms.

Authors:  Ulrike Lindequist; Timo H J Niedermeyer; Wolf-Dieter Jülich
Journal:  Evid Based Complement Alternat Med       Date:  2005-09       Impact factor: 2.629

6.  Effects of Ganodermanondiol, a New Melanogenesis Inhibitor from the Medicinal Mushroom Ganoderma lucidum.

Authors:  Ji-Woong Kim; Hong-Il Kim; Jong-Hyeon Kim; O-Chul Kwon; Eun-Suk Son; Chang-Soo Lee; Young-Jin Park
Journal:  Int J Mol Sci       Date:  2016-10-27       Impact factor: 5.923

Review 7.  Use of Ganoderma lucidum (Ganodermataceae, Basidiomycota) as Radioprotector.

Authors:  Aránzazu González; Violeta Atienza; Alegría Montoro; Jose M Soriano
Journal:  Nutrients       Date:  2020-04-19       Impact factor: 5.717

8.  Ergosterol Peroxide from the Medicinal Mushroom Ganoderma lucidum Inhibits Differentiation and Lipid Accumulation of 3T3-L1 Adipocytes.

Authors:  Yong-Un Jeong; Young-Jin Park
Journal:  Int J Mol Sci       Date:  2020-01-10       Impact factor: 5.923

Review 9.  Ganoderma lucidum: Unutilized natural medicine and promising future solution to emerging diseases in Africa.

Authors:  M A Oke; F J Afolabi; O O Oyeleke; T A Kilani; A R Adeosun; A A Olanbiwoninu; E A Adebayo
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.